TD Cowen lowered the firm’s price target on Biogen (BIIB) to $275 from $300 and keeps a Buy rating on the shares. The firm said they reported Q3 revenue in line and EPS beat. 2024 EPS guidance was raised. Leqembi s launch continues to gain momentum but logistics and capacity constraints remain barriers to adoption.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue